Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Details
- Category
- weight-loss
- Administration
- Subcutaneous injection (weekly)
- Prescription Required
- Yes
- Also known as
- LY3437943
Common Uses
- Weight loss
- Metabolic health
- Appetite suppression
- Blood sugar regulation